Yescarta
Manufacturing · United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
United StatesWebsite
www.yescartatecartusrems.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About Yescarta
YESCARTA and TECARTUS REMS is a Risk Evaluation and Mitigation Strategy program established by the FDA for the management of YESCARTA and TECARTUS, two genetically modified autologous T cell immunotherapies aimed at treating adult patients with specific types of large B-cell lymphoma. The products are available exclusively through enrolled hospitals and clinics that comply with REMS requirements to ensure safe administration. The primary intended clientele includes healthcare professionals within the US, focusing on those administering treatments for hematologic malignancies. The program emphasizes the importance of monitoring for potential severe side effects, including cytokine release syndrome and neurologic toxicities.Explore more
Popular SearchesYescartaKite Pharma IncRisk Evaluation and Mitigation StrategySIC Code 28,283NAICS Code 32,325Show moreSell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Yescarta your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Yescarta
Funding: Get notified immidiatlly once Yescarta has new funding data
Earning: See what the market has to say on Yescarta recently announced quarterly report
Check if Yescarta has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Yescarta launches new products
Check out if Yescarta is spiking on competitors!
Website visits: Recent activity has been detected on your website
Click to see if Yescarta had a recent Job posting/layoffs
Yescarta, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Find VP level buyers at Yescarta
Find 2 more new buyers
Compare Similar Companies to Yescarta
Compare insights from companies similar to Yescarta, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Yescarta
<$5M
11-50
Private
-
-
N/A
Yescarta Tech Stack
A closer look at the technologies used by Yescarta
Yescarta News & Media
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Yescarta
Sign Up For FreeTo access detailed company insights
YESCARTA and TECARTUS REMS is a Risk Evaluation and Mitigation Strategy program established by the FDA for the management of YESCARTA and TECARTUS, two genetically modified autologous T cell immunotherapies aimed at treating adult patients with specific types of large B-cell lymphoma. The products are available exclusively through enrolled hospital... Read More
